Literature DB >> 21742967

Soluble proteins induce strong CD8+ T cell and antibody responses through electrostatic association with simple cationic or anionic lipopeptides that target TLR2.

Brendon Y Chua1, David Pejoski, Stephen J Turner, Weiguang Zeng, David C Jackson.   

Abstract

The low immunogenicity exhibited by most soluble proteins is generally due to the absence of molecular signatures that are recognized by the immune system as dangerous. In this study, we show that electrostatic binding of synthetic branched cationic or anionic lipopeptides that contain the TLR-2 agonist Pam(2)Cys markedly enhance a protein's immunogenicity. Binding of a charged lipopeptide to oppositely charged protein Ags resulted in the formation of stable complexes and occurs at physiologic pH and salt concentrations. The induction of cell-mediated responses is dependent on the electrostatic binding of lipopeptide to the protein, with no CD8(+) T cells being elicited when protein and lipopeptide possessed the same electrical charge. The CD8(+) T cells elicited after vaccination with lipopeptide-protein Ag complexes produced proinflammatory cytokines, exhibited in vivo lytic activity, and protected mice from challenge with an infectious chimeric influenza virus containing a single OVA epitope as part of the influenza neuraminidase protein. Induction of a CD8(+) T cell response correlated with the ability of lipopeptide to facilitate Ag uptake by DCs followed by trafficking of Ag-bearing cells into draining lymph nodes. Oppositely charged but not similarly charged lipopeptides were more effective in DC uptake and trafficking. Very high protein-specific Ab titers were also achieved by vaccination with complexes composed of oppositely charged lipopeptide and protein, whereas vaccination with similarly charged constituents resulted in significant but lower Ab titers. Regardless of whether similarly or oppositely charged lipopeptides were used in the induction of Ab, vaccination generated dominant IgG1 isotype Abs rather than IgG2a.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21742967     DOI: 10.4049/jimmunol.1100486

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells.

Authors:  Melissa Santone; Susanna Aprea; Tom Y H Wu; Michael P Cooke; M Lamine Mbow; Nicholas M Valiante; James S Rush; Stephanie Dougan; Ana Avalos; Hidde Ploegh; Ennio De Gregorio; Cecilia Buonsanti; Ugo D'Oro
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine.

Authors:  Annette Fox; Kylie M Quinn; Kanta Subbarao
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

3.  Reducing the impact of influenza-associated secondary pneumococcal infections.

Authors:  Edin J Mifsud; Amabel C Tan; Kirsty R Short; Lorena E Brown; Brendon Y Chua; David C Jackson
Journal:  Immunol Cell Biol       Date:  2015-07-21       Impact factor: 5.126

4.  Vaccine-Specific Immune Responses against Mycobacterium ulcerans Infection in a Low-Dose Murine Challenge Model.

Authors:  Brendon Y Chua; Timothy P Stinear; Kirstie M Mangas; Andrew H Buultjens; Jessica L Porter; Sarah L Baines; Estelle Marion; Laurent Marsollier; Nicholas J Tobias; Sacha J Pidot; Kylie M Quinn; David J Price; Katherine Kedzierska; Weiguang Zeng; David C Jackson
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

5.  Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant.

Authors:  Abbi L Engel; Guan-Cheng Sun; Ekram Gad; Lauren R Rastetter; Katie Strobe; Yi Yang; Yushe Dang; Mary L Disis; Hailing Lu
Journal:  Immunobiology       Date:  2013-05-13       Impact factor: 3.144

Review 6.  Immunopotentiating and Delivery Systems for HCV Vaccines.

Authors:  Alexander K Andrianov; Thomas R Fuerst
Journal:  Viruses       Date:  2021-05-25       Impact factor: 5.048

7.  Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses.

Authors:  Brendon Y Chua; Douglas Johnson; Amabel Tan; Linda Earnest-Silveira; Toshiki Sekiya; Ruth Chin; Joseph Torresi; David C Jackson
Journal:  PLoS One       Date:  2012-10-16       Impact factor: 3.240

8.  Activated human nasal epithelial cells modulate specific antibody response against bacterial or viral antigens.

Authors:  Chiou-Yueh Yeh; Te-Huei Yeh; Chiau-Jing Jung; Pei-Lin Chen; Huei-Ting Lien; Jean-San Chia
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

Review 9.  Evolving Bacterial Envelopes and Plasticity of TLR2-Dependent Responses: Basic Research and Translational Opportunities.

Authors:  Junbin Li; Dennis Sang Won Lee; Joaquín Madrenas
Journal:  Front Immunol       Date:  2013-10-28       Impact factor: 7.561

Review 10.  Universal immunity to influenza must outwit immune evasion.

Authors:  Sergio Quiñones-Parra; Liyen Loh; Lorena E Brown; Katherine Kedzierska; Sophie A Valkenburg
Journal:  Front Microbiol       Date:  2014-06-12       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.